Constance Okeke

1 month ago | ophthalmologytimes.com | Constance Okeke |Sheryl Stevenson

Constance Okeke, MD, MSCE, summarized research posters presented by her mentees—Siddharth Bhargava, MD; Taylor Drake, BS; Kush Shah, BS—at the 2025 American Glaucoma Society Annual Meeting, held from February 26 to March 2 in Washington, DC. The posters highlighted the 1-year outcomes of the Streamline surgical system in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).

Dec 12, 2024 | healio.com | Constance Okeke |Eamon Dreisbach |Anthony DeFino

You've successfully added Glaucoma in Ophthalmology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from the AAO meeting, Constance O.

Nov 1, 2024 | glaucomaphysician.net | Constance Okeke

In ophthalmology, the administration of topical medications is a cornerstone for glaucoma management. However, commercially available drop sizes (30+ µL) exceed the eye’s capacity to retain the medication (7-10 µL), leading to excessive dosing, overflow, periorbital irritation, and drainage by the nasolacrimal ducts causing systemic absorption. The increased risk of systemic adverse effects (AEs), particularly with drug classes like beta-blockers, has additional implications for patient safety.

Mar 5, 2024 | optometrytimes.com | Lynda Charters |Constance Okeke

Latanoprostene bunod 0.024% (LBN) (Vyzulta, Bausch & Lomb), a prostaglandin analog (PGA), received FDA approval in 2017 based on data obtained in 2 prospective randomized, clinical trials of 840 patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). First author Constance Okeke, MD, MSCE, and colleagues took those results a step further and evaluated the performance of LBN in a real-world clinical setting,1 which can differ substantially from that in randomized clinical trials.